Publications

Publications Search

Search for publications by author
Search for publications by abstract keyword(s)

Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer

Abstract

The emergence of immunotherapy has been an astounding breakthrough in cancer treatments. In particular, immune checkpoint inhibitors, targeting PD-1 and CTLA-4, have shown remarkable therapeutic outcomes. However, response rates from immunotherapy have been reported to be varied, with some having pronounced success and others with minimal to no clinical benefit. An important aspect associated with this discrepancy in patient response is the immune-suppressive effects elicited by the tumour microenvironment (TME). Immune suppression plays a pivotal role in regulating cancer progression, metastasis, and reducing immunotherapy success. Most notably, myeloid-derived suppressor cells (MDSC), a heterogeneous population of immature myeloid cells, have potent mechanisms to inhibit T-cell and NK-cell activity to promote tumour growth, development of the pre-metastatic niche, and contribute to resistance to immunotherapy. Accumulating research indicates that MDSC can be a therapeutic target to alleviate their pro-tumourigenic functions and immunosuppressive activities to bolster the efficacy of checkpoint inhibitors. In this review, we provide an overview of the general immunotherapeutic approaches and discuss the characterisation, expansion, and activities of MDSCs with the current treatments used to target them either as a single therapeutic target or synergistically in combination with immunotherapy.

Type Journal
ISBN 2073-4409 (Electronic) 2073-4409 (Linking)
Authors Law, A. M. K.; Valdes-Mora, F.; Gallego-Ortega, D.
Responsible Garvan Author Dr David Gallego-Ortega
Publisher Name Cells
Published Date 2021-02-27
Published Volume 9
Published Issue 3
Status Published in-print
DOI 10.3390/cells9030561
URL link to publisher's version https://www.ncbi.nlm.nih.gov/pubmed/32121014